N/A
N=100
Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder
Obsessive-Compulsive Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00389493 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcome: Primary: Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) — 26.1; 27.2; 25.9; 22.6 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Risperidone (Drug); Exposure/ritual prevention therapy (EX/RP) (Behavioral); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- New York State Psychiatric Institute
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) |
26.1; 27.2; 25.9; 22.6; 13.0; 23.1 | — |
| SECONDARY Social Adjustment Scale-SR |
2.3; 2.3; 2.2; 2.2; 1.9; 2.1 | — |
| SECONDARY Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form |
52.3; 57.8; 56.1; 55.1; 70.2; 62.6 | — |
| SECONDARY Hamilton Depression Rating Scale (Ham-D) |
9.8; 7.8; 7.7; 8.0; 7.8; 7.7 | — |
| SECONDARY Brown Assessment of Beliefs (BABS) |
5.7; 6.1; 5.3; 4.5; 2.4; 4.3 | — |
Summary
This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.
Eligibility Criteria
Inclusion Criteria
- Primary diagnosis of OCD
- Currently on a stable and adequate dose of an SRI
- Sufficient severity of symptoms to warrant additional augmentation treatment
Exclusion Criteria
- Medical or psychiatric conditions that would make participation in the study unsafe
- Currently receiving psychotherapy elsewhere at the time of study entry
- Previously (within 12 weeks prior to study entry) attended 8 or more sessions of EX/RP within a 2-month period or received at least 4 weeks of antipsychotic augmentation while on an adequate SRI dose
- Currently being treated with an SRI for the first time and has not yet responded, but has not tried another SRI
Data sourced from ClinicalTrials.gov (NCT00389493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.